Keytruda is currently the only PD-1/PD-L1 inhibitor approved for advanced cervical cancer, one of the most common tumour types in women with 14,500 new cases diagnosed every year in the US, and ...

So, right now, the standard of care for advanced cervical cancer, if you are a candidate for immunotherapy, is actually to receive four drugs at the same time, two chemotherapies, a platinum-based ...